Business Wire

THALES

21.9.2020 09:02:42 CEST | Business Wire | Press release

Share
Thales Empowers Organisations to Simplify the Discovery, Protection and Control of Sensitive Data

Thales today announced the launch of the CipherTrust Data Security Platform , the industry’s first unified data protection solution that enables organisations to discover, protect, and control their most sensitive data wherever it resides. The new platform helps solve key challenges they face today. These include data security complexity caused by multi-cloud adoption, evolving global and regional privacy regulations, as well as the risk of data breaches from external and internal threats.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005046/en/

Drawing from years of data protection innovation, Thales has built the CipherTrust Data Security Platform to seamlessly unify data discovery, classification and data protection, along with strong access controls and centralised key management. The ‘all-in-one’ platform combines the best of Thales’s Vormetric and SafeNet KeySecure technologies to give organisations the power to keep sensitive data secure on premises or in the cloud while reducing costs and maintaining the highest levels of compliance assurance.

“CipherTrust Data Security Platform unifies the most critical elements of data security – data discovery, protection and control – into one integrated platform, providing powerful tools to address the evolving global and regional privacy regulations as well as the uptick of cloud adoption intensified by remote working,” said Todd Moore, Vice President, Encryption Solutions, Thales . “In addition to the external challenges of data protection, our new platform also helps reduce the operational complexities many organisations face, especially as businesses work to recover from the effects of the COVID-19 pandemic. This evolution of security through simplicity is exactly what organisations require now and for the future.”

Solving the Complexity Problem

Highly-distributed workforces, evolving regulations and technologies, infinite data growth and the exploding use of multi-cloud services puts sensitive data at risk, and makes data security even more challenging. According to the 2020 Thales Data Threat Report - Global Edition, organisations use 29 different cloud services on average. Lack of visibility and operational complexity has resulted in organisations not knowing where all of their sensitive data is stored. This concern around complexity (identified as the number one barrier to security by nearly 40% of the 2020 Thales Data Threat Report-Global Edition respondents) is simplified with the CipherTrust Data Security Platform.

“Complexity is one of the main barriers to deploying data security more broadly, in part because overall data security remains fairly specialised and siloed, forcing enterprises to manage multiple vendors and point products,” said Garrett Bekker, Senior Research Analyst, Information Security at 451 Research, part of S&P Global Market Intelligence, in the report, ‘Thales unites KeySecure and Vormetric product lines under CipherTrust Data Security Platform.’ “With the launch of CipherTrust Data Security Platform, Thales is looking to simplify the delivery of data security with one of the broadest data security portfolios in the market, spanning most flavours of encryption (application, database, server, file), vaulted and vaultless tokenisation, masking, key management, cloud key management, and HSMs and most recently, data discovery.”

Discover and classify sensitive data in the cloud and on-premises

As more enterprise applications and data move to the cloud and companies seek to improve scalability and deliver remote capabilities for their workforce, IT organisations will be challenged to have a holistic view of their data. As part of the platform, CipherTrust Data Discovery and Classification enables organisations to discover and classify sensitive data, as well as remediate, from a single pane of glass. Organisations can understand risks, uncover gaps, and make better decisions about both third-party data sharing and cloud migration. In addition, the solution provides a comprehensive set of built-in classification templates for commonly requested data privacy and security regulations, such as the GDPR and California Consumer Privacy Act (CCPA), but is flexible enough to handle custom policies based on specific patterns and algorithms.

Protect sensitive data anywhere with advanced encryption and tokenisation

According to IDC, more than 175 zetabytes of data will be created by 2025, and today more than half of all corporate data is stored in the cloud. To address the complexity of where data is stored, the CipherTrust Data Security Platform offers strong capabilities for securing and controlling access to sensitive data in databases, files and containers. Specific technologies include:

  • CipherTrust Transparent Encryption – encrypts data across on-premises, cloud, database, file, and Big Data environments with comprehensive data access controls and detailed data access audit logging that can stop the most malicious attacks;
  • CipherTrust Database Protection – provides transparent column-level encryption of structured, sensitive data residing in databases, such as credit card, social security numbers, national ID numbers, passwords and email addresses;
  • CipherTrust Application Data Protection – offers APIs for developers to quickly add encryption and other crypto functions to their applications, while SecOps controls the encryption keys;
  • CipherTrust Tokenisation– offers application-level data tokenisation services in two convenient solutions that deliver customer flexibility--Vaultless Tokenisation with policy-based Dynamic Data Masking and Vaulted Tokenisation; and
  • CipherTrust Batch Data Transformation – provides static data masking services to remove sensitive data from production databases so compliance and security concerns are alleviated when sharing a database with third parties for analytics, testing, or other processing.

Control and centralise management of encryption keys

The accelerated adoption of encryption has led to the need to manage a far larger number of encryption keys across traditional data stores and multiple cloud environments. Proper management of encryption keys is paramount for data security because if keys are stolen, the encryption is rendered useless, and if they are lost the data is digitally shredded and cannot be recovered. This is why many organisations struggle with managing different key management solutions. CipherTrust Data Security Platform’s enterprise key management enables businesses to centrally manage and establish strong controls over encryption keys and policies for data encrypted on-premises and by cloud services. Specific technologies include:

  • CipherTrust Manager– centralises keys, management and data access policies for all CipherTrust Data Security Platform products and is available in both physical and virtual form factors that are up to FIPS 140-2 Level 3 compliant;
  • CipherTrust Cloud Key Manager – offers cloud bring you own key (BYOK) life cycle management for many Infrastructure, Platform- and Software as a Service cloud providers;
  • CipherTrust KMIP Server – centralises key management for the standard Key Management Interoperability Protocol (KMIP) commonly used across storage solutions; and,
  • CipherTrust TDE Key Manager – centralises key management for encryption found in Oracle, SQL, and Always Encrypted SQL.

Industry insight and views on the latest data security trends can be found on the Thales blog . Follow Thales on Twitter , LinkedIn , Facebook and YouTube .

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT

Thales Group

Security

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye